Navigation Links
Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
Date:2/7/2008

SEATTLE, Feb. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., chairman and chief executive officer of Dendreon, will present a company update at the 10th Annual BIO CEO & Investor Conference in New York City, on Wednesday, February 13, 2008 at 1:15 p.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
2. Dendreon Reports Third Quarter 2007 Financial Results
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Secures $130 Million Committed Equity Financing Facility
5. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
8. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
9. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
10. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 ... of the "Global N-acetylcysteine Industry Report 2014" ... The Global N-acetylcysteine Industry Report 2014 is a ... of the global N-acetylcysteine industry. The ... including definitions, classifications, applications and industry chain structure. ...
(Date:9/18/2014)... ST. LOUIS , Sept. 18, 2014  U.S. ... portfolio by signing an exclusive license for technology developed ... to control gene expression in plants, including for applications ... species. The technology was developed under ... science officer at Kultevat and former president of the ...
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 /PRNewswire/ ... en 1974, a été depuis ... compléter les évaluations cliniques traditionnelles par des ... Outcomes) et sur les impacts économiques des ... A cours d,une ...
(Date:9/18/2014)... dysplasia is a group of rare diseases that ... cartilage. Its onset hits at the fetal stage ... in the gene encoding fibroblast growth factor receptor ... of skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal ... and is often lethal, and achondroplasia (ACH), which ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... June 21, 2011 ,   ... the,appointment of Matthew Roe as Chief Business Officer. ... Senior Director,Business Development & Licensing. During ... in,licensing, alliance management, acquisition, divestment, and sales,and marketing, ...
... surfaces with features below 100 nanometres have numerous ... this way, Tecnalia participates in a intragated FP7 ... processes, based on nanoimprinting techniques (NIL), as a ... The main benefits followed are cost reduction, simpler ...
... are two classes of fundamental particles. Photons, the quanta ... that make up atomic nuclei belong to the fermions. ... very basic level. This difference is expressed in their ... fundamental particle was postulated, which was dubbed the anyon. ...
Cached Biology Technology:Crescendo Biologics Appoints Matthew Roe as Chief Business Officer 2Acrobatics for anyons: New test for elusive fundamental particle proposed 2
(Date:9/18/2014)... will be celebrated tonight at the third annual Golden ... health of premature infants and in paving the way ... work was supported by the National Science Foundation, the ... Commission, will be honored at a ceremony at the ... of Members of Congress will be on hand to ...
(Date:9/18/2014)... global cycles of carbon and nitrogen comprise all ... and environmental systems have caused imbalances and perturbations ... gases (GHGs). Increased GHGs result in climate changes ... ecosystems, oceans and the atmosphere. Understanding these feedback ... branch of environmental science during the past three ...
(Date:9/18/2014)... when people are too stressed they are often grouchy, ... Mind Institute (BMI) at EPFL have just highlighted a ... stress and the loss of social skills and cognitive ... synaptic regulatory molecule in the brain. This was revealed ... , Carmen Sandi,s team went to look for ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Greenhouse gas research enters a new era 2How stress tears us apart 2
... December 24, 2008 A study from a team of ... Development Research Unit at the IRCM, and Dr. Dayana Krawchuk, ... the developing limb control nerve targeting from the spinal cord ... scientists from Columbia University in New York City, is published ...
... The University of Texas School of Public Health recently described ... community-acquired antibiotic-resistant Staph ylococcus aureus (CA MRSA) ... The Panton Valentine leukocidin is made up of ... produced by community-acquired methicillin-resistant S. aureus (CA MRSA). ...
... Women should go for the broccoli when the ... While it has been known for some time ... cabbage, can help prevent breast cancer, the mechanism by ... proliferation was unknown until now. Scientists in ...
Cached Biology News:Motor nerve targeting to limb muscles is controlled by ephrin proteins 2UT Public Health researchers find link to severe Staph infections 2UCSB scientists show how certain vegetables combat cancer 2
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
The Protein Kinase Factsbooks (2 Volume Set)...
... Walker (1996) • This book offers ... studying proteins and peptides. Each tried ... instruction, timesaving troubleshooting tips, alternative procedures, ... reagents and suppliers. Topics covered range ...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Biology Products: